184 patents currently held
62 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next US patent term in the University Health Network portfolio ends in Jun 2027, and more of its terms end in 2034 (22) than in any other year. from the record
Of the 62 now held by other companies, 10 name Novo Nordisk a S as their current owner, and 52 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
19
Ending by 2030
Jun 2027
Next term end
131
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends May 2035 · Medium confidence
Also notable
Ends Jun 2032 · High confidence
Also notable
Ends Mar 2036 · High confidence
Also notable
Ends Aug 2039 · High confidence
Also notable
Ends May 2037 · High confidence
Also notable
Ends Apr 2031 · High confidence
Also notable
Ends Jun 2036 · High confidence
Also notable
Ends Aug 2033 · High confidence
Method and Apparatus for Quantitative and Depth Resolved Hyperspectral Fluorescence and Reflectance Imaging for Surgical Guidance
US 11,510,600
Cited by 80 later US patents, top 1% of utility patents granted in 2022 in our data. Protection runs to 2035.
Device and Method for Wound Imaging and Monitoring
US 9,042,967
The most cited patent in this portfolio, cited by 285 later US patents, top 1% of utility patents granted in 2015 in our data. Protection runs to 2032.
Collection and Analysis of Data for Diagnostic Purposes
US 11,676,276
Cited by 26 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2036.
Method for Expansion of Double Negative Regulatory T Cells
US 11,534,460
Cited by 12 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2039.
Methods of Capturing Cell-Free Methylated DNA and Uses of Same
US 11,560,558
Cited by 4 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2037. A terminal disclaimer caps this term to an earlier patent's.
Synthesis of Chiral 2-(1H-INDAZOL-6-YL)-SPIRO[CYCLOPROPANE-1,3'-Indolin]-2'-ONES
US 9,579,327
Cited by 17 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
HPK1 Inhibitors and Methods of Using Same
US 10,501,474
Cited by 11 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2036.
Antibodies to TTR and Methods of Use
US 9,534,048
Cited by 30 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 30, 2026The maintenance fee for Device and Method for Determining Depth and Concentration of a Subsurface Fluorescent Object (US 11,662,315) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
- 4 fees due Dec 6 to 13, 2026 · next Dec 6
- 7 fees due Jan 2 to 30, 2027 · next Jan 2
- 4 fees due Feb 22 to 27, 2027 · next Feb 22
- 7 fees due Mar 3 to 26, 2027 · next Mar 3
- 3 fees due Apr 8 to 17, 2027 · next Apr 8
- 3 fees due May 12 to 21, 2027 · next May 12
- 4 fees due Jun 3 to 30, 2027 · next Jun 3
- 2 fees due Jul 2 to 23, 2027 · next Jul 2
- 4 fees due Aug 16 to 25, 2027 · next Aug 16
- 4 fees due Sep 5 to 24, 2027 · next Sep 5
- 3 fees due Oct 9 to 16, 2027 · next Oct 9
- 3 fees due Nov 7 to 19, 2027 · next Nov 7
Recent changes
- 5 of the patents on this record were granted since Aug 24, 2026
- 3 terms have ended since Aug 24, 2026
- Oct 23 US 10,106,545 Pyrazolopyrimidine Compounds · lapsed on the fee record
- Sep 18 US 10,077,255 Synthesis of Chiral 2-(1H-INDAZOL-6-YL)-SPIRO[CYCLOPROPANE-1,3'-Indolin]-2'-ONES · lapsed on the fee record
- Aug 26 US 8,818,058 Method for Determining a Correction Function for Correcting Computed Tomographic Numbers of a Small Target Object in a CT Image · lapsed on the fee record
What they patent
The largest of its 131 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,803,523 | Whole Blood Preparation for Cytometric Analysis of Cell Signaling Pathways held by University Health Network and Beckman Coulter, Inc. In force · High confidence | In force | High confidence | |
| US 8,119,978 | Apparatus and Methods for Real-Time Verification of Radiation Therapy In force · High confidence | In force | High confidence | |
| US 9,925,220 | Method of Expanding Double Negative T Cells In force · High confidence | In force | High confidence | |
| US 9,545,231 | Optimized Aperture Selection Imaging Computed Tomography System and Method In force · High confidence | In force | High confidence | |
| US 10,258,653 | IL-12 Immunotherapy for Cancer In force · Medium confidence | In force | Medium confidence | |
| US 7,898,407 | Hand Hygiene Compliance System In force · High confidence | In force | High confidence | |
| US 8,725,234 | Systems, Devices, and Methods Employing Fiber Optic Shape Tracking In force · High confidence | In force | High confidence | |
| US 8,403,224 | Apparatus, System and Method for Tracking Drugs During a Repackaging and Administering Process In force · High confidence | In force | High confidence | |
| US 9,439,980 | Thymidylate Kinase Fusions and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,137,205 | Thymidylate Kinase Fusions and Uses Thereof In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 184: 62 patents in force now held by others · 97 patents ended · 135 applications pending · 198 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.